首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1962957

全球溶瘤病毒免疫疗法市场：市场机会、技术平台、已批准疗法剂量、定价及临床试验展望（至2031年）

Global Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031

出版日期: 2026年03月01日 | 出版商:

KuicK Research | 英文 410 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球溶瘤病毒免疫疗法市场机会、技术平台、已批准疗法剂量、定价及临床试验洞察2031年报告的主要发现和亮点：

到2031年，全球溶瘤病毒免疫疗法市场机会：超过 50亿美元
已核准的溶瘤病毒免疫疗法数量：3 种
已批准溶瘤病毒免疫疗法的可用性、剂量和定价分析
本报告涵盖的溶瘤病毒免疫疗法临床试验：超过 150 种
依公司、适应症和临床试验类型划分的溶瘤病毒免疫疗法临床试验洞察阶段
市售溶瘤病毒免疫疗法的临床现状
溶瘤病毒免疫疗法开发中使用的专有平台：本报告涵盖超过15种
溶瘤病毒免疫疗法与其他治疗药物合併应用概述

溶瘤病毒免疫疗法的必要性及本报告的意义

溶瘤病毒免疫疗法是肿瘤免疫学领域最令人振奋且发展最快的治疗选择之一。溶瘤病毒能够选择性地感染、复製和破坏肿瘤细胞，同时诱导全身性抗肿瘤免疫反应，其治疗潜力已广泛研究。然而，由于肿瘤学领域目前面临许多挑战，例如肿瘤异质性、免疫逃脱机制以及对传统治疗方案日益增强的抗药性，传统的单一标靶或单机制肿瘤药物开发方法正变得越来越不适用。溶瘤病毒的双重作用机制，即透过直接溶解肿瘤细胞和活化免疫系统发挥作用，为应对肿瘤学领域的复杂挑战提供了差异化的治疗机会。

溶瘤病毒疗法的临床有效性已通过多种溶瘤病毒药物的批准得到证实，例如中国的Oncoline、美国和欧盟的Imligic以及日本的Delitac。除了已核准的溶瘤病毒药物外，目前全球还有大量溶瘤病毒药物临床试验中，这些药物单独或与免疫检查点抑制剂和细胞疗法共同开发，用于治疗黑色素瘤、胶质母细胞瘤、头颈癌、肺癌和其他实体肿瘤。

本报告对全球溶瘤病毒免疫疗法市场进行了全面、前瞻性的分析。报告分析了溶瘤病毒免疫疗法市场的临床、监管、技术和策略格局，以及竞争格局。随着多种溶瘤病毒药物进入中后期临床试验，竞争格局发生显着变化。

本报告包含的临床试验洞察

溶瘤病毒免疫疗法市场成长和发展的关键因素之一是临床开发，这将继续在市场的成熟过程中发挥关键作用。因此，目前进行各种临床试验，以评估安全性、最佳化给药方案、比较全身性和肿瘤内给药途径，并评估其在多种肿瘤适应症中的治疗效果。本报告全面系统性地阐述了从早期首次人体临床试验到后期验证性试验的临床试验情况。

溶瘤病毒免疫疗法药物临床试验和开发的关键方面之一是Replimune Group, Inc.的RP1（也称为vusolimogene oderparepvec）。它目前正处于后期临床开发阶段，与免疫检查点抑制剂联合用于治疗晚期黑色素瘤患者。儘管监管流程复杂且包括大量审查，但持续的对话和第三期临床试验的确认是人们对溶瘤病毒免疫疗法药物及其在未来肿瘤治疗方案中的作用信心日益增强的重要指标。

活跃于溶瘤病毒免疫疗法研发领域的主要公司

溶瘤病毒免疫疗法市场的竞争格局由众多生技公司和跨国製药公司共同塑造。生物技术公司在病毒载体和基因有效载荷技术的创新和进步方面处于领先地位，而跨国製药公司也致力于拓展其自主研发的溶瘤病毒免疫疗法产品组合。

Merck & Co.、Bristol-Myers Squibb、Astellas Pharma、Roche等企业在免疫疗法领域占据战略地位，其中许多公司已经在评估和开发基于病毒的解决方案。同时，Calidi Biotherapeutics, Inc.、Lokon Pharma、TILT Biotherapeutics、Genelux Corporation、Candel Therapeutics 和 Imugene Limited 等生物技术公司开发创新病毒载体和新型免疫刺激有效载荷。

这些因素，加上科学创新、策略联盟和全球临床部署，为免疫疗法的发展创造了令人振奋的环境。亚洲新进业者的崛起也促进了下一代腺病毒和干细胞衍生病毒载体的开发，进一步丰富了竞争格局。

技术平台、合作关係与协定

溶瘤病毒免疫疗法的开发需要先进的技术平台，这些平台可用于最佳化病毒特异性、刺激免疫系统、改进生产流程并增强病毒的系统稳定性。各公司正致力于开发可用于插入免疫刺激基因（例如细胞激素和免疫检查点抑制剂）的专有技术平台。

策略联盟已成为免疫疗法领域的关键特征。生技公司与大型製药公司之间的合作有助于成本分摊、拓展临床能力并加快监管审批流程。例如，Carivia Immunotherapeutics 已与Roche公司合作，以评估病毒疗法与现有免疫疗法的联合应用。澳洲生物技术公司 Imugene Limited 与中国生物技术公司 JW Therapeutics 的合作也表明，人们对将病毒疗法与 CAR-T 细胞疗法相结合的兴趣日益浓厚。

生产合作也非常重要，尤其是在 GMP 规模下生产病毒面临许多技术挑战的情况下。此类合作在研发和商业化规划过程中变得越来越重要。这些合作将共同促进平台模组化，并加速向临床应用的过渡。

报告揭示溶瘤病毒免疫疗法领域未来发展方向

报告也指出，关键的溶瘤病毒免疫疗法候选药物有望进入后期研发阶段。此外，关键的临床结果有望成为溶瘤病毒免疫疗法领域发展和应用的重要转捩点。同时，联合疗法的研发预计将持续扩展，溶瘤病毒免疫疗法作为一种免疫诱导剂，在癌症治疗的多维度方法中具有巨大潜力，未来或将成为主要的癌症治疗选择。

溶瘤病毒免疫疗法领域的未来发展和研究可能侧重于最佳化全身给药方法、开发增强型免疫载荷以及开发用于识别合适癌症患者群体的生物标记。总而言之，监管支持机制的建立、机构对该领域的投资增加以及产业合作的建立，有望促进溶瘤病毒免疫疗法的未来发展和广泛应用。这很可能使溶瘤病毒免疫疗法在未来成为全球癌症治疗领域不可或缺乏的一部分。

AdCure Bio
Adze Biotechnology
Akamis Bio
Beijing SyngenTech
Beijing WellGene Biotech
BioVex Inc. (Amgen)
Calidi Biotherapeutics
Creative Biolabs
Genelux Corporation
Immvira Pharma
KaliVir
Lokon Pharma
Oncolys BioPharma
Seneca Therapeutics
Shanghai Sunway Biotech
SillaJen Biotherapeutics
Takara Bio
TILT Biotherapeutics
Transgene
Virogin Biotech

简介目录图表

Global Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031 Report Findings & Highlights:

Global Oncolytic Virus Immunotherapy Market Opportunity By 2031: > USD 5 Billion
Number Of Approved Oncolytic Virus Immunotherapies: 3 Therapies
Approved Oncolytic Virus Immunotherapy Availability, Dosage & Price Analysis
Oncolytic Viruses Immunotherapies In Clinical Trials Included In Report: > 150 Therapies
Insight On Oncolytic Viruses Immunotherapies In Clinical Trials By Company, Indication & Phase
Marketed Oncolytic Viruses Immunotherapies Clinical
Proprietary Platforms Used For Developing Oncolytic Virus Immunotherapy: > 15 In Report
Oncolytic Virus Immunotherapy Combinations With Other Therapeutic Agents Overview

Need For Oncolytic Virus Immunotherapy & Why This Report?

Oncolytic virus immunotherapy is one of the most exciting and rapidly advancing therapeutic options within the immuno oncology space. The therapeutic potential of oncolytic viruses, which selectively infect, replicate, and destroy tumor cells while generating systemic anti-tumor immune responses, has been extensively studied. With the challenges that the oncology therapeutic space is currently facing, from tumor heterogeneity to immune escape mechanisms, and the rise of resistance to conventional therapeutic options, the traditional single-target or single mechanism approaches to oncology drug development have become increasingly inadequate. The dual mechanism of oncolytic viruses, which work through direct tumor lysis and immune system activation, offers a differentiated therapeutic opportunity to address the complex challenges of oncology.

The clinical validity of this therapeutic modality has been proved through the approval of oncolytic virus-based therapies like Oncorine in China, Imlygic in the US and EU, and Delytact in Japan. In addition to the approved oncolytic virus-based drugs, there is a significant global pipeline of oncolytic virus-based drugs currently under clinical investigation for the treatment of melanoma, glioma, head and neck cancer, lung cancer, and other solid tumors, alone or in combination with immune checkpoint inhibitors and cell therapy.

This report is a comprehensive and forward looking report on the global oncolytic virus immunotherapy market. It analyzes the clinical, regulatory, technology, and strategic landscape of the oncolytic virus immunotherapy market, and the competitive dynamics of the oncolytic virus market that is currently undergoing significant change with the initiation of several oncolytic virus-based drugs into the mid and late stages of clinical trials.

Clinical Trials Insight Included In Report

One of the significant aspects of the growth and development of the oncolytic virus immunotherapy market is clinical development and how it will continue to play an important role in the maturation of the market itself. As such, various clinical trials are currently underway and are assessing safety, dosing regimen optimization, systemic versus intratumoral delivery routes of administration, and therapeutic activity across a wide range of different oncology indications. Our report provides a comprehensive and structured understanding of clinical trials from first-in-human early-stage clinical trials through to late-stage confirmatory trials.

One of the significant aspects of clinical trials and their role in the development of oncolytic virus immunotherapy drugs is RP1 or vusolimogene oderparepvec by Replimune Group, Inc., currently undergoing late-stage clinical development in combination with checkpoint inhibitors in patients with advanced melanoma. Although it must be said that regulatory processes are complex and involve significant review processes, ongoing dialogue and confirmation of Phase 3 clinical trials are a significant indicator of the growing credibility of oncolytic virus immunotherapy drugs and their role in the future of oncology treatment protocols.

Major Companies Active In R&D Of Oncolytic Virus Immunotherapies

The competitive landscape of the oncolytic virus immunotherapy market is dominated by a wide range of different biotechnology innovators and multinational pharmaceutical corporations. While it must be said that biotechnology firms have led the way in terms of innovation and advancements in viral backbone and genetic payload technology, multinational pharmaceutical corporations are increasingly looking to develop and expand their own portfolios of oncolytic virus immunotherapy drugs.

Companies such as Merck & Co., Bristol-Myers Squibb, Astellas Pharma, and Roche are strategically placed in the immunotherapy landscape, with many already evaluating or working on viral-based solutions. On the other hand, biotechnology companies such as Calidi Biotherapeutics, Inc., Lokon Pharma, TILT Biotherapeutics, Genelux Corporation, Candel Therapeutics, and Imugene Limited are working on innovative viral vectors and novel immune stimulatory payloads.

This creates an exciting environment for the development of immunotherapies, with elements of scientific innovation, strategic partnership, and clinical expansion across the world. The emergence of new players in Asia is also contributing to the development of the next generation of adenoviral vectors as well as stem cell-derived viral vectors, thus diversifying the competitive landscape.

Technology Platforms, Collaborations & Agreements

The development of oncolytic virus immunotherapies requires sophisticated technology platforms that can be utilized for the optimization of the specificity of the viruses, the stimulation of the immune system, the manufacturing process, as well as the systemic stability of the viruses. Companies are increasingly focusing on developing proprietary technology platforms that can be utilized for the insertion of immune-stimulatory genes such as cytokines or checkpoint inhibitors.

Strategic partnerships have become an important characteristic of the immunotherapy landscape. The partnerships between biotechnology companies and large pharmaceutical companies facilitate the sharing of costs, expansion of clinical capabilities, as well as the acceleration of the regulatory process. For instance, KaliVir Immunotherapeutics, Inc. has entered into a partnership with Roche for the evaluation of the viral therapy with existing immunotherapies. The partnerships between companies such as Imugene Limited, an Australian biotech, and JW Therapeutics, a Chinese biotech, also illustrate the increased interest in the combination of viral therapies with CAR-T cell therapies.

Manufacturing partnerships are also important, especially due to the technical challenge of viral production at GMP scale. Such partnerships are becoming increasingly integral to the development and commercialization planning process. These partnerships will collectively help to support the modularity of the platforms and speed up the process of translating them into the clinic.

Report Indicating Future Direction Of Oncolytic Virus Immunotherapy Segment

The report also indicates that the leading oncolytic virus immunotherapy candidates are likely to move into the late-stage development pipeline in the future. Moreover, the key clinical results are likely to be major inflection points in the development and acceptance of the oncolytic virus immunotherapy segment in the future. Additionally, the development of combination strategies is likely to continue to expand in the future, which may result in oncolytic virus immunotherapy becoming the prime choice in the treatment of cancer in the future due to its ability to be used as an immune primer in the multidimensional treatment of cancer.

The future development and research in the oncolytic virus immunotherapy segment are likely to be directed towards the optimization of systemic delivery, the development of enhanced immune payloads, and the development of biomarkers to identify the right kind of cancer patients in the future. Overall, the future development and acceptance of the oncolytic virus immunotherapy segment are likely to be supported through the development of regulatory support mechanisms, the increasing trend of institutional investment in the sector, and the development of partnerships in the sector, which is likely to result in the oncolytic virus immunotherapy segment becoming an integral part of the global cancer treatment sector in the future.

1. Research Methodology

2. Introduction To Oncolytic Virus Therapy

2.1 Overview
2.2 Need For Oncolytic Virus Immunotherapy

3. Globally Approved Oncolytic Virus Immunotherapies

3.1 Commercially Approved Therapies
3.2 Regulatory Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME,

RMAT, RPDD

4. Global Oncolytic Virus Immunotherapy Market Trend & Developments

4.1 Current Market Outline
4.2 Future Market Opportunities

5. Global Oncolytic Virus Immunotherapies Clinical Trials Overview

5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Oncolytic Virus Immunotherapies Clinical Trials By Company, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase 0
6.4 Phase I
6.5 Phase I/II
6.6 Phase II
6.7 Phase II/III
6.8 Phase III
6.9 Registered

7. Marketed Oncolytic Virus Immunotherapies Clinical Insight

8. Global Oncolytic Virus Immunotherapy Market Trends By Region

8.1 US
8.2 Europe
8.3 South Korea
8.4 Japan
8.5 Australia
8.6 UK
8.7 China

9. Global Oncolytic Virus Immunotherapy Market Trends By Indications

9.1 Melanoma
9.2 Head & Neck Cancer
9.3 Brain Cancers
9.4 Gynecological Cancers
9.5 Hematological Malignancies
9.6 Lung Cancer
9.7 Pancreatic Cancer
9.8 Breast Cancer
9.9 Prostate Cancer
9.10 Hepatocellular Carcinoma

10. Global Oncolytic Virus Immunotherapy - Availability, Dosage & Price Analysis

10.1 Imlygic
- 10.1.1 Overview & Patent Insights
- 10.1.2 Pricing & Dosage
10.2 Oncorine (H101)
- 10.2.1 Overview
- 10.2.2 Pricing & Dosage
10.3 Delytact
- 10.3.1 Overview
- 10.3.2 Pricing & Dosage

11. Platforms Used For Developing Advanced Oncolytic Virus Immunotherapy

12. Oncolytic Virus Immunotherapy Combinations With Other Therapeutic Agents

12.1 Oncolytic Virus Immunotherapy With Nanomaterials
12.2 Oncolytic Virus Immunotherapy With Chemotherapy
12.3 Oncolytic Virus Immunotherapy With Immunotherapy
12.4 Oncolytic Virus Immunotherapy With Epigenetic Therapy

13. Global Oncolytic Virus Immunotherapy Market Dynamics

13.1 Market Drivers
13.2 Market Challenges

14. Competitive Landscape

14.1 AdCure Bio
14.2 Adze Biotechnology
14.3 Akamis Bio
14.4 Beijing SyngenTech
14.5 Beijing WellGene Biotech
14.6 BioVex Inc. (Amgen)
14.7 Calidi Biotherapeutics
14.8 Creative Biolabs
14.9 Genelux Corporation
14.10 Immvira Pharma
14.11 KaliVir
14.12 Lokon Pharma
14.13 Oncolys BioPharma
14.14 Seneca Therapeutics
14.15 Shanghai Sunway Biotech
14.16 SillaJen Biotherapeutics
14.17 Takara Bio
14.18 TILT Biotherapeutics
14.19 Transgene
14.20 Virogin Biotech

简介目录图表

List of Figures

Figure 2-1: Oncolytic Viruses - Mechanism Of Action
Figure 2-2: Categorization Of Oncolytic Viruses
Figure 2-3: Illustration Of Major Events In Clinical Virotherapy
Figure 2-4: Transition From Natural Infection To Genetic Engineering
Figure 2-5: Tumor Immune "Field-Like" Defense & Viral Counteraction
Figure 2-6: Oncolytic Virus Immunotherapy - Double-Edged Sword Model
Figure 5-1: Global - Oncolytic Virus Immunotherapies Clinical Trials By Phase (Numbers), 2026 -2031
Figure 5-2: Global - Oncolytic Virus Immunotherapies Clinical Trials By Country (Numbers), 2026 2031
Figure 5-3: Global - Oncolytic Virus Immunotherapies Clinical Trials By Company (Numbers), 2026 2031
Figure 5-4: Global - Oncolytic Virus Immunotherapies Clinical Trials By Indication (Numbers), 2026 - 2031
Figure 5-5: Global - Oncolytic Virus Immunotherapies Clinical Trials By Priority Status (Numbers), 2026 - 2031
Figure 9-1: HCC 22-138 Phase I Study (NCT06216938) - Initiation & Completion Year
Figure 9-2: IGNYTE Phase II Study (NCT03767348) - Initiation & Completion Year
Figure 9-3: IGNYTE-3 Phase III Study (NCT06264180) - Initiation & Completion Year
Figure 9-4: ARTACUS Phase I/II Study (NCT04349436) - Initiation & Completion Year
Figure 9-5: OH2-I-ST-01 Phase I/II Study (NCT04386967) - Initiation & Completion Year
Figure 9-6: 16-557 Phase I Study (NCT03152318) - Initiation & Completion Year
Figure 9-7: Ad5-TD-nsIL-12 Phase I Study (NCT05717712) - Initiation & Completion Year
Figure 9-8: Ad-TD-nsIL12 Phase I Study (NCT05717699) - Initiation & Completion Year
Figure 9-9: OnPrime Phase III Study (NCT05281471) - Initiation & Completion Year
Figure 9-10: TILT-123 - Mode of Action
Figure 9-11: PROTA Phase I/II Study (NCT05271318) - Initiation & Completion Year
Figure 9-12: VM-002-101 Phase I Study (NCT06910657) - Initiation & Completion Year
Figure 9-13: STEALTH-001 Phase I Study (NCT06444815) - Initiation & Completion Year
Figure 9-14: NCI-2017-00049 Phase I Study (NCT06508463) - Initiation & Completion Year
Figure 9-15: NCI-2017-00049 Phase I Study (NCI-2017-00049) - Initiation & Completion Year
Figure 9-16: 2026-0013 Phase I Study (NCT07398963) - Initiation & Completion Year
Figure 9-17: LuTK02 Phase II Study (NCT04495153) - Initiation & Completion Year
Figure 9-18: Tilt-T610 Phase I Study (NCT06125197) - Initiation & Completion Year
Figure 9-19: VIRO-25 Phase II Study (NCT06463665) - Initiation & Completion Year
Figure 9-20: RADNET Phase I/II Study (NCT02749331) - Initiation & Completion Year
Figure 9-21: GOBLET Phase II Study (NCT07280377) - Initiation & Completion Year
Figure 9-22: TBI1401-03 Phase I Study (NCT03252808) - Initiation & Completion Year
Figure 9-23: MCC-18621 Phase I/II Study (NCT02779855) - Initiation & Completion Year
Figure 9-24: NCI-2020-02940 Phase II Study (NCT04445844) - Initiation & Completion Year
Figure 9-25: BRACELET-1 Phase II Study (NCT04215146) - Initiation & Completion Year
Figure 9-26: PrTK03 Phase III Study (NCT01436968) - Initiation & Completion Year
Figure 9-27: VM-002-101 Phase I Study (NCT06910657) - Initiation & Completion Year
Figure 9-28: VG161-C102 Phase I Study (NCT04806464) - Initiation & Completion Year
Figure 9-29: VG161-A201 Phase II Study (NCT05223816) - Initiation & Completion Year
Figure 9-30: VG161-C203 Phase I/II Study (NCT06124001) - Initiation & Completion Year
Figure 9-31: RP2-003 Phase II Study (NCT05733598) - Initiation & Completion Year
Figure 9-32: CHN-PLAGH-BT-096 Phase I Study (NCT07018518) - Initiation & Completion Year
Figure 9-33: GONGCHU Phase I Study (NCT06508307) - Initiation & Completion Year
Figure 10-1: US - Cost Of Supply Of c 1 mpfu/mL & 100 mpfu/mL (US$), May'2024
Figure 10-2: Imlygic - Dose For Initial Treatment Cycle & Subsequent Treatment Cycle (Million PFU/ml)
Figure 10-3: Imlygic - Duration Of Initial & Subsequent Treatment Cycle (weeks)
Figure 10-4: Imlygic - Average Price Of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$)
Figure 10-5: Imlygic - Maximum Volume Administered by Size of Lesion (ml)
Figure 11-1: Calidi Biotherapeutics Platform
Figure 11-2: Candel Therapeutics - enLIGHTEN
Figure 11-3: Codagenix - Core Concept
Figure 11-4: Codagenix OV Platform Manufacturing Benefitrs
Figure 11-5: Genelux - Choice Discovery platform
Figure 11-6: Imugene - OnCARlytics
Figure 11-7: KaliVir Immunotherapeutics - VET Backbone Technology
Figure 11-8: Lokon Pharma - LOAd Technology
Figure 11-9: SyngenTech - Synthetic Gene Circuit
Figure 11-10: SyngenTech - Synov OV Platform
Figure 11-11: ValoTx - PeptiCRAd
Figure 11-12: ValoTx - PeptiENV
Figure 11-13: ValoTx - PeptiVAX / PeptiENV / PeptiBAC
Figure 11-14: Virogin - Transcription & Translation Dual Regulation backbone
Figure 11-15: Virogin In Situ Personalized Tumor Vaccine - Abscopal effect
Figure 11-16: Vyriad - Oncolytic Virus Platforms
Figure 12-1: Combination Of Oncolytic Virus With Other Therapies
Figure 12-2: Combination Of Oncolytic Virus Immunotherapy With Nanomaterials
Figure 12-3: Oncolytic Virus Immunotherapy & Nanomaterials - Mode Of Action
Figure 13-1: Global Oncolytic Virus Immunotherapy - Market Drivers
Figure 13-2: Global Oncolytic Virus Immunotherapy - Market Challenges

List of Tables

Table 2-1: Comparison Of Conventional Therapy vs Oncolytic Virotherapy
Table 2-2: Oncolytic Virotherapy - Advantages & Challenges
Table 2-3: Why Cancer Cells Are More Susceptible To Oncolytic Viruses
Table 3-1: Approved Oncolytic Virus Immunotherapies
Table 3-2: Oncolytic Virus Therapies Granted Regulatory Designations
Table 10-1: Imlygic - Recommended Dose & Schedule
Table 12-1: Oncolytic Virus & Nanomaterial Combination Therapy - Advantages
Table 12-2: How Chemotherapy Enhances Oncolytic Virus Therapy
Table 12-3: Immunotherapeutic Modalities Combined With Oncolytic Viruses
Table 12-4: Epigenetic Therapy & Oncolytic Viruses Combination - Advantages

02-2729-4219

+886-2-2729-4219

License/价格

全球溶瘤病毒免疫疗法市场：市场机会、技术平台、已批准疗法剂量、定价及临床试验展望（至2031年）

Global Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031

目录

第1章研究方法

第2章溶瘤病毒疗法概论

第3章全球已核准的溶瘤病毒免疫疗法

第4章全球溶瘤病毒免疫疗法市场的趋势与发展

第5章全球溶瘤病毒免疫疗法临床试验概况

第6章全球溶瘤病毒免疫疗法临床试验（依公司、适应症和阶段划分）

第7章市售溶瘤病毒免疫疗法的临床见解

第8章溶瘤病毒免疫疗法市场区域趋势

第9章溶瘤病毒免疫疗法市场趋势（依适应症划分）

第10章全球溶瘤病毒免疫疗法 - 供应、剂量与价格分析

第11章用于开发先进溶瘤病毒免疫疗法的平台

第12章溶瘤病毒免疫疗法与其他疗法的合併应用

第13章全球溶瘤病毒免疫疗法市场动态

第14章竞争格局